ALBANY, N.Y., March 14, 2016 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) today announced that it has been recognized as a Life
Science Leader CMO Leadership Award recipient in the categories
of Expertise (overall, small pharma), Capabilities (small pharma)
and Compatibility (small pharma). In 2013, AMRI was awarded a CMO
Leadership Award in the Quality category.
This year's awards will be presented at the CMO Leadership
Awards Ceremony and Reception at the W Hotel on Wednesday, March 16, 2016 in New York City. Each year, recipients are
evaluated by executives and managers of the CMO's sponsors in five
categories, which include Capabilities, Compatibility, Expertise,
Quality, and Reliability.
"We are honored to be acknowledged once again as a CMO
Leadership Award Winner," said William S.
Marth, President and CEO, AMRI. "This recognition
underscores how our customers and peers feel about working with us
and the confidence they have in our expertise. This award comes at
an extraordinary time for our company. It is a pivotal time for
AMRI as we continue to dramatically expand our services building a
strong platform for our business and a stronger pharmaceutical
development and manufacturing company for tomorrow's pharmaceutical
market. We are pleased to receive the award and would like to
congratulate the rest of the CMO award winners."
To establish this year's winners, Life Science Leader
worked with Industry Standard Research (ISR). ISR's Contract
Manufacturing Quality Benchmarking research is conducted annually
via an online survey. For the 2016 CMO Awards data, 83 contract
manufacturers were evaluated on 26 different performance metrics.
Research participants were recruited from biopharmaceutical
companies of all sizes and were screened for decision-making
influence and authority when it comes to working with contract
manufacturing suppliers. Respondents only evaluated companies with
which they have worked on an outsourced project within the past 18
months. This level of qualification ensured that quality ratings
came from actual involvement with a business and that companies
identified as leaders were backed by experiential data.
AMRI, which is a fast-growing contract research, development and
manufacturing company serving the brand and generic
pharmaceutical markets, is growing a portfolio of complex API.
The company enters 2016 with an API manufacturing pipeline that
includes 50 compounds in Phase I and II and 14 in Phase III, with
27 DMFs and 148 commercial products. On the drug product side,
there are 69 aseptic fill finish products in Phase I and II, 21 in
Phase III, with 23 under regulatory review and 17 in commercial
production.
About AMRI
Albany Molecular Research Inc. (AMRI)
is a global contract research and manufacturing organization that
has been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America, Europe and Asia,
our key business segments include Discovery and Development
Services (DDS), Active Pharmaceutical Ingredients (API), and Drug
Product Manufacturing (DPM). Our DDS segment provides comprehensive
services from hit identification to IND, including expertise with
diverse chemistry, library design and synthesis, in vitro biology
and pharmacology, drug metabolism and pharmacokinetics, as well as
natural products. API supports the chemical development and cGMP
manufacture of complex API, including potent and cytotoxic
compounds, controlled substances, steroids, peptides, hormones, and
sterile API. DPM supports development through commercial scale
production of complex liquid-filled and lyophilized parenterals,
sterile suspensions and ophthalmic formulations. For more
information about AMRI, please visit our website at
www.amriglobal.com or follow us on Twitter (@amriglobal).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-wins-four-life-science-leader-awards-300234902.html
SOURCE AMRI